INDSWFTLABPharmaceuticals
Ind Swift Laboratories Ltd — Profit & Loss Statement
₹131.43
+0.97%
Ind Swift Laboratories Ltd Profit & Loss Statement (Annual)
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Cost Of Revenue | 762.15 Cr | 766.86 Cr | 629.12 Cr | 516.24 Cr |
| Total Revenue | 1.28K Cr | 1.21K Cr | 1.04K Cr | 891.34 Cr |
| Operating Revenue | 1.28K Cr | 1.21K Cr | 1.04K Cr | 891.34 Cr |
| Tax Effect Of Unusual Items | 107.14 Cr | -8.31 Cr | -4.10 Cr | 0.00 |
| Tax Rate For Calcs | 0.28 | 0.30 | 0.30 | 0.30 |
| Normalized EBITDA | 292.93 Cr | 257.99 Cr | 248.69 Cr | 198.65 Cr |
| Total Unusual Items | 388.82 Cr | -27.71 Cr | -13.67 Cr | 0.00 |
| Total Unusual Items Excluding Goodwill | 388.82 Cr | -27.71 Cr | -13.67 Cr | 0.00 |
| Net Income From Continuing Operation Net Minority Interest | 420.96 Cr | 47.60 Cr | -2.15 Cr | -3.15 Cr |
| Reconciled Depreciation | 53.30 Cr | 57.36 Cr | 131.04 Cr | 87.29 Cr |
| Reconciled Cost Of Revenue | 762.15 Cr | 766.86 Cr | 629.12 Cr | 516.24 Cr |
| EBITDA | 681.75 Cr | 230.28 Cr | 235.02 Cr | 198.65 Cr |
| EBIT | 628.45 Cr | 172.91 Cr | 103.99 Cr | 111.36 Cr |
| Net Interest Income | -32.73 Cr | -86.29 Cr | -94.98 Cr | -99.70 Cr |
| Interest Expense | 46.69 Cr | 86.39 Cr | 91.45 Cr | 93.35 Cr |
| Interest Income | 18.37 Cr | 5.87 Cr | 0.56 Cr | 0.51 Cr |
| Normalized Income | 139.28 Cr | 66.99 Cr | 7.42 Cr | -3.15 Cr |
| Net Income From Continuing And Discontinued Operation | 420.96 Cr | 47.60 Cr | -2.15 Cr | -3.15 Cr |
| Total Expenses | 1.07K Cr | 1.03K Cr | 946.31 Cr | 780.38 Cr |
| Rent Expense Supplemental | 0.86 Cr | 0.75 Cr | 0.52 Cr | 0.54 Cr |
| Diluted Average Shares | 5.91 Cr | 5.91 Cr | 5.91 Cr | 5.91 Cr |
| Basic Average Shares | 5.91 Cr | 5.91 Cr | 5.91 Cr | 5.91 Cr |
| Diluted EPS | 71.24 | -4.28 | -4.28 | -4.28 |
| Basic EPS | 71.24 | -4.28 | -4.28 | -4.28 |
| Diluted NI Availto Com Stockholders | 420.96 Cr | 47.60 Cr | -2.15 Cr | -3.15 Cr |
| Net Income Common Stockholders | 420.96 Cr | 47.60 Cr | -2.15 Cr | -3.15 Cr |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 420.96 Cr | 47.60 Cr | -2.15 Cr | -3.15 Cr |
| Net Income Including Noncontrolling Interests | 420.96 Cr | 47.60 Cr | -2.15 Cr | -3.15 Cr |
| Net Income Discontinuous Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Continuous Operations | 420.96 Cr | 47.60 Cr | -2.15 Cr | -3.15 Cr |
| Tax Provision | 160.31 Cr | 38.69 Cr | 14.68 Cr | 21.16 Cr |
| Pretax Income | 581.76 Cr | 86.52 Cr | 12.53 Cr | 18.01 Cr |
| Other Non Operating Income Expenses | 0.08 Cr | 0.92 Cr | 14.00 Cr | 3.48 Cr |
| Special Income Charges | 388.82 Cr | -27.71 Cr | -13.67 Cr | 0.00 |
| Other Special Charges | -388.82 Cr | 26.71 Cr | 6.57 Cr | — |
| Impairment Of Capital Assets | 0.00 | 1.00 Cr | 7.10 Cr | 0.00 |
| Net Non Operating Interest Income Expense | -32.73 Cr | -86.29 Cr | -94.98 Cr | -99.70 Cr |
| Total Other Finance Cost | 4.41 Cr | 5.77 Cr | 4.09 Cr | 6.86 Cr |
| Interest Expense Non Operating | 46.69 Cr | 86.39 Cr | 91.45 Cr | 93.35 Cr |
| Interest Income Non Operating | 18.37 Cr | 5.87 Cr | 0.56 Cr | 0.51 Cr |
| Operating Income | 215.03 Cr | 181.52 Cr | 92.42 Cr | 110.96 Cr |
| Operating Expense | 303.72 Cr | 258.93 Cr | 317.19 Cr | 264.14 Cr |
| Other Operating Expenses | 33.53 Cr | 10.03 Cr | 8.31 Cr | 4.07 Cr |
| Depreciation And Amortization In Income Statement | 53.30 Cr | 57.36 Cr | 131.04 Cr | 87.29 Cr |
| Depreciation Income Statement | 53.30 Cr | 57.36 Cr | 131.04 Cr | 87.29 Cr |
| Selling General And Administration | 79.58 Cr | 63.58 Cr | 64.41 Cr | 48.11 Cr |
| Selling And Marketing Expense | 42.80 Cr | 43.06 Cr | 44.00 Cr | 32.17 Cr |
| General And Administrative Expense | 36.78 Cr | 20.52 Cr | 20.41 Cr | 15.95 Cr |
| Rent And Landing Fees | 0.86 Cr | 0.75 Cr | 0.52 Cr | 0.54 Cr |
| Gross Profit | 518.75 Cr | 440.45 Cr | 409.61 Cr | 375.10 Cr |
| Research And Development | — | — | 32.72 Cr | 33.01 Cr |
| Average Dilution Earnings | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Ind Swift Laboratories Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.